Climb Bio Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, Climb Bio stock has a consensus rating of "Strong Buy" and an average price target of $28.4. The average 1-year stock price forecast is 174.13% higher than the current stock price, while the lowest is $18 (+73.75%) and the highest is $40 (+286.10%).

Price Target: $28.4 (+174.13%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$18	$28.4	$28	$40
Change	+73.75%	+174.13%	+170.27%	+286.10%

Analyst Ratings

The average analyst rating for Climb Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26	Nov '26
Strong Buy	14	13	13	13	14	14
Buy	1	1	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	14	15	15	16	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ilya Zubkov Freedom Capital Markets	Freedom Capital Markets	Buy Maintains $20 → $26	Buy	Maintains	$20 → $26	+150.97%	Nov 10, 2026
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $30	Buy	Reiterates	$30	+189.58%	Nov 9, 2026
Danielle Brill Truist Financial	Truist Financial	Buy Maintains $25	Buy	Maintains	$25	+141.31%	Nov 6, 2026
Laura Chico Wedbush	Wedbush	Buy Maintains $25 → $27	Buy	Maintains	$25 → $27	+160.62%	Nov 6, 2026
Unknown Analyst Oppenheimer No rating	Oppenheimer	Buy Reiterates $25	Buy	Reiterates	$25	+141.31%	Nov 6, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

625.00K

EPS This Year

-0.75

from -0.88

EPS Next Year

-0.99

from -0.75

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-35.67M	-45.14M	-21.47M	-27.00M	-67.88M	-65.45M
Net Income	-47.48M	-45.24M	-35.12M	-73.90M	-59.85M	-57.93M
EPS	-	-	-	-	-0.88	-0.75
Free Cash Flow	-	-	-	-	-54.54M	-59.33M
No. Analysts	-	-	-	-	-	15

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.74
Avg	-0.75
Low	-0.77

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-